MedTrace Logo

Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

NCT03951077 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2022-06-08

Study results available
· View outcomes & findings →

Summary

This study will assess the potential impact of elagolix on disordered pituitary and ovarian hormones in women with polycystic ovary syndrome (PCOS).

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Elagolix

Capsule administered orally

DRUG

Placebo

Capsule administered orally

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-12
Primary Completion
2021-02-10
Completion
2021-02-10
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03951077 on ClinicalTrials.gov